Penerangan produk
Indikasi
1.1 KISQALI® FEMARA® CO-PACK (HR) 2 (HER2) II III , 1.2 KISQALI® FEMARA® CO-PACK (HR) 2 (HER2)
Mekanisme Tindakan
(CDK) 4 6 D- , , D-CDK4/6 (pRb) , pRb , G1
Farmakologi
12.1 Mekanisme Tindakan (CDK) 4 6 D- , , D-CDK4/6 (pRb) , pRb , G1
Dos dan Cara Penggunaan
2.1 KISQALI FEMARA CO-PACK , 28 KISQALI FEMARA CO-PACK [ (12.3)] KISQALI FEMARA CO-PACK / , (LHRH) KISQALI FEMARA CO-PACK, ,
Langkah Berjaga-jaga
5.1 / KISQALI CDK4/6 (ILD) / 400 mg KISQALI (NSAI) NATALEE ,1.5% ILD/ 1-2 KISQALI MONALEESA-2 MONALEESA-7 ,1.2% ILD/ , 0.3% 3-4 ILD/ , [ (6.2)] , / ,
Kontraindikasi
FEMARA FEMARA
Interaksi Ubat
7.1 CYP3A4 CYP3A4 [ (12.3)] , QTcF [ Langkah Berjaga-jaga (5.3)] CYP3A KISQALI , CYP3A , KISQALI CYP3A , KISQALI 200 mg
Kesan Sampingan
/ [ Langkah Berjaga-jaga(5.1)] [ Langkah Berjaga-jaga(5.2)] QT [ Langkah Berjaga-jaga(5.3)] [ Langkah Berjaga-jaga(5.4)] [ Langkah Berjaga-jaga(5.5)] 6.1 , , Langkah Berjaga-jaga Description
Penyimpanan
KISQALI FEMARA , 28 KISQALI 200 , , , , “RIC”, “NVR”
